Kilitch Drugs (India) Ltd
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]
- Market Cap ₹ 554 Cr.
- Current Price ₹ 323
- High / Low ₹ 500 / 265
- Stock P/E 20.1
- Book Value ₹ 152
- Dividend Yield 0.00 %
- ROCE 15.7 %
- ROE 12.6 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 159% CAGR over last 5 years
- Company's median sales growth is 28.3% of last 10 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -5.46%
- Company has a low return on equity of 9.50% over last 3 years.
- Earnings include an other income of Rs.12.6 Cr.
- Company has high debtors of 156 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 108 | 19 | 21 | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 154 | 198 | 209 | |
| 95 | 21 | 25 | 28 | 45 | 75 | 53 | 63 | 104 | 122 | 130 | 167 | 178 | |
| Operating Profit | 13 | -2 | -4 | -1 | 6 | 7 | 0 | 5 | 10 | 18 | 24 | 32 | 32 |
| OPM % | 12% | -9% | -19% | -2% | 11% | 9% | 1% | 8% | 9% | 13% | 16% | 16% | 15% |
| 92 | 3 | 2 | 1 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 11 | 13 | |
| Interest | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 | 5 | 6 |
| Depreciation | 5 | 2 | 10 | 10 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 3 |
| Profit before tax | 97 | -1 | -12 | -9 | 6 | 9 | 2 | 5 | 10 | 12 | 19 | 34 | 35 |
| Tax % | 22% | -70% | -4% | -5% | 16% | 55% | 48% | 27% | 35% | 31% | 30% | 28% | |
| 76 | -0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 14 | 25 | 26 | |
| EPS in Rs | 52.99 | -0.20 | -7.77 | -6.17 | 3.46 | 2.29 | 0.50 | 2.18 | 4.36 | 6.18 | 8.34 | 15.26 | 15.77 |
| Dividend Payout % | 52% | 0% | 0% | 0% | 13% | 20% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 30% |
| 3 Years: | 20% |
| TTM: | 33% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 42% |
| 5 Years: | 159% |
| 3 Years: | 54% |
| TTM: | 68% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 27% |
| 3 Years: | 27% |
| 1 Year: | -2% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 17 |
| Reserves | 101 | 107 | 95 | 88 | 98 | 106 | 103 | 112 | 124 | 136 | 160 | 186 | 248 |
| 9 | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 32 | 49 | 84 | |
| 54 | 7 | 8 | 11 | 15 | 13 | 12 | 61 | 50 | 46 | 32 | 61 | 49 | |
| Total Liabilities | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 399 |
| 9 | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | 64 | 64 | |
| CWIP | 0 | 0 | 0 | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 6 | 47 | 98 |
| Investments | 138 | 72 | 49 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 | 72 | 77 |
| 30 | 46 | 25 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | 129 | 160 | |
| Total Assets | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 399 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29 | -8 | 17 | 1 | 1 | 0 | 4 | 46 | 6 | 3 | -2 | 18 | |
| 41 | -31 | -20 | -2 | -4 | -14 | -10 | -38 | -15 | 8 | -8 | -40 | |
| -9 | -0 | 0 | -0 | 6 | 17 | 1 | 2 | 7 | -1 | 9 | 13 | |
| Net Cash Flow | 2 | -39 | -2 | -0 | 2 | 3 | -5 | 10 | -2 | 10 | -1 | -9 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 243 | 286 | 196 | 148 | 86 | 109 | 122 | 132 | 142 | 149 | 156 |
| Inventory Days | 12 | 124 | 110 | 84 | 39 | 36 | 70 | 35 | 28 | 10 | 18 | 53 |
| Days Payable | 19 | 124 | 154 | 184 | 108 | 33 | 89 | 525 | 239 | 200 | 118 | 189 |
| Cash Conversion Cycle | 44 | 243 | 241 | 96 | 79 | 89 | 89 | -367 | -79 | -48 | 50 | 20 |
| Working Capital Days | -143 | 197 | 234 | 115 | 93 | 37 | 22 | -223 | -40 | -4 | 30 | 56 |
| ROCE % | 8% | -10% | -9% | 5% | 6% | 1% | 3% | 6% | 10% | 13% | 16% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Copy publication of extract of financial results for the quarter ended 30th September, 2025
-
Monitoring Agency Report
14 Nov - No-deviation monitoring report for Rs49.92cr rights issue; Rs18.30cr used for Pen project; Rs30.54cr in FDs.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
14 Nov - H1 FY26 PAT Rs10.30 crore; rights issue 13,98,463 shares at Rs357 totaling Rs49.93 crore.
-
Board Meeting Outcome for Outcome Of Board Meeting
13 Nov - Approved Q2 results; rights issue 13,98,463 shares raising Rs4,992.51 lakh; Rs5,150.32 lakh capex for Pen.
-
Unaudited Financial Results For The Quarter Ended 30Th September, 2025
13 Nov - Unaudited Q2/Q1 FY26 results; rights issue raised Rs4,992.51 lakhs; Pen greenfield capex.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Jun 2024TranscriptPPT
-
Jun 2023TranscriptPPT
Business Overview:[1]
KDL is a pharmaceutical company engaged in developing, manufacturing, marketing, and exporting various Pharmaceutical Formulations in dosage forms like Solid, Liquid, and Parental.